Bepirovirsen

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney DiseaseChronic HepatitisHepatitis BChronic Hepatitis B Virus InfectionHepatitis B, Chronic

105 competitors in Kidney Disease

#DrugCompanyPhaseTrials

1

Sensipar

Amgen

Approved

22

Kerendia

Bayer

Approved

13

Maxipime

Pfizer

Approved

—4

Afinitor

Novartis

Approved

—5

Medrol

Pfizer

Approved

—6

Vimpat

UCB

Approved

—7

Xtandi

Astellas

Approved

—8

Tafinlar

Novartis

Approved

—9

Norvir

AbbVie

Approved

—10

Neoral

Novartis

Approved

—Show 39 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hepatitis B3 trials

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Completed·GSK·Phase 1·NCT06422767·46 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment

Active, not recruiting·GSK·Phase 2·NCT06497504·153 enrolled

A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study

Active, not recruiting·GSK·Phase 2·NCT04954859·360 enrolled

Chronic Hepatitis b2 trials

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1)

Completed·GSK·Phase 3·NCT05630807·981 enrolled

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)

Completed·GSK·Phase 3·NCT05630820·857 enrolled

Chronic Hepatitis1 trial

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Active, not recruiting·GSK·Phase 1/2·NCT05330455·74 enrolled

Kidney Disease1 trial

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

Recruiting·GSK·Phase 1·NCT07168356·32 enrolled

Adult1 trial

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

Completed·GSK·Phase 1·NCT06058390·160 enrolled

2 more indications

Hepatitis B, Chronic1 trial

Bepirovirsen Liver Biopsy Study

Not yet recruiting·NNational University Health System, Singapore·Phase 2·NCT07696520·30 enrolled

Chronic Hepatitis B Virus Infection1 trial

A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)

Active, not recruiting·GSK·Phase 2·NCT06537414·283 enrolled

Details

Drug Info

Related News